Literature DB >> 19060127

Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes.

Aaron P Kellogg1, Kimber Converso, Tim Wiggin, Martin Stevens, Rodica Pop-Busui.   

Abstract

Glucose-mediated oxidative stress and the upregulation of cyclooxygenase (COX)-2 pathway activity have been implicated in the pathogenesis of several vascular complications of diabetes including diabetic neuropathy. However, in nondiabetic subjects, the cardiovascular safety of selective COX-2 inhibition is controversial. The aim of this study was to explore the links between hyperglycemia, oxidative stress, activation of the COX-2 pathway, cardiac sympathetic integrity, and the development of left ventricular (LV) dysfunction in experimental diabetes. R wave-to-R wave interval (R-R interval) and parameters of LV function measured by echocardiography using 1% isoflurane, LV sympathetic nerve fiber density, LV collagen content, and markers of myocardial oxidative stress, inflammation, and PG content were assessed after 6 mo in control and diabetic COX-2-deficient (COX-2(-/-)) and littermate, wild-type (COX-2(+/+)) mice. There were no differences in blood glucose, LV echocardiographic measures, collagen content, sympathetic nerve fiber density, and markers of oxidative stress and inflammation between nondiabetic (ND) COX-2(+/+) and COX-2(-/-) mice at baseline and thereafter. After 6 mo, diabetic COX-2(+/+) mice developed significant deteriorations in the R-R interval and signs of LV dysfunction. These were associated with a loss of LV sympathetic nerve fiber density, increased LV collagen content, and a significant increase in myocardial oxidative stress and inflammation compared with those of ND mice. Diabetic COX-2(-/-) mice were protected against all these biochemical, structural, and functional deficits. These data suggest that in experimental diabetes, selective COX-2 inactivation confers protection against sympathetic denervation and LV dysfunction by reducing intramyocardial oxidative stress, inflammation, and myocardial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060127      PMCID: PMC2643890          DOI: 10.1152/ajpheart.00678.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  67 in total

1.  High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway.

Authors:  Meei Ling Sheu; Feng Ming Ho; Rong Sen Yang; Kuo Fang Chao; Wan Wan Lin; Shoei Yn Lin-Shiau; Shing-Hwa Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-01-13       Impact factor: 8.311

2.  The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Authors:  James R Sowers; William B White; Bertram Pitt; Andrew Whelton; Lee S Simon; Nathaniel Winer; Alan Kivitz; Hein van Ingen; Thomas Brabant; John G Fort
Journal:  Arch Intern Med       Date:  2005-01-24

3.  Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils.

Authors:  M Pouliot; C Gilbert; P Borgeat; P E Poubelle; S Bourgoin; C Créminon; J Maclouf; S R McColl; P H Naccache
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

Review 4.  Diabetes mellitus and cardiac function.

Authors:  M A Mahgoub; A S Abd-Elfattah
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction.

Authors:  Rodica Pop-Busui; Ian Kirkwood; Helena Schmid; Victor Marinescu; Justin Schroeder; Dennis Larkin; Elina Yamada; David M Raffel; Martin J Stevens
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

6.  Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes.

Authors:  H Schmid; L A Forman; X Cao; P S Sherman; M J Stevens
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

7.  Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

Authors:  J E Dinchuk; B D Car; R J Focht; J J Johnston; B D Jaffee; M B Covington; N R Contel; V M Eng; R J Collins; P M Czerniak
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

8.  Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy.

Authors:  M J Stevens; F Dayanikli; D M Raffel; K C Allman; T Sandford; E L Feldman; D M Wieland; J Corbett; M Schwaiger
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

9.  Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis.

Authors:  J Díez; A Panizo; M J Gil; I Monreal; M Hernández; J Pardo Mindán
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

Review 10.  Prostaglandin endoperoxide synthase: why two isoforms?

Authors:  C S Williams; R N DuBois
Journal:  Am J Physiol       Date:  1996-03
View more
  17 in total

1.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Alexander A Obrosov; Viktor R Drel; Jerry L Nadler; Irina G Obrosova; Mark A Yorek
Journal:  J Diabetes Mellitus       Date:  2013-08

Review 3.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

Review 4.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

5.  Increased serum gamma-glutamyltransferase levels are associated with ventricular instability in type 2 diabetes.

Authors:  Kun Wang; Ling Li; Yang Wu; Yu Yang; Jie Chen; Danyu Zhang; Zhoujun Liu; Juan Xu; Meng Cao; Xiaodong Mao; Chao Liu
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

6.  Differential impact of type-1 and type-2 diabetes on control of heart rate in mice.

Authors:  Catherine L Stables; David S Auerbach; Steven E Whitesall; Louis G D'Alecy; Eva L Feldman
Journal:  Auton Neurosci       Date:  2015-12-17       Impact factor: 3.145

Review 7.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

8.  Atherosclerosis and leukocyte-endothelial adhesive interactions are increased following acute myocardial infarction in apolipoprotein E deficient mice.

Authors:  Andrew P Wright; Miina K Öhman; Takanori Hayasaki; Wei Luo; Hana M Russo; Chiao Guo; Daniel T Eitzman
Journal:  Atherosclerosis       Date:  2010-06-18       Impact factor: 5.162

9.  Cyclooxygenase 2, toll-like receptor 4 and interleukin 1β mRNA expression in atherosclerotic plaques of type 2 diabetic patients.

Authors:  Alessandro Baldan; Silvia Ferronato; Silvia Olivato; Giovanni Malerba; Alberto Scuro; Gian Franco Veraldi; Matteo Gelati; Sergio Ferrari; Sara Mariotto; Pier Franco Pignatti; Sara Mazzucco; Macarena Gomez-Lira
Journal:  Inflamm Res       Date:  2014-08-06       Impact factor: 4.575

10.  p38 MAP kinase inhibitor reverses stress-induced myocardial dysfunction in vivo.

Authors:  Fangping Chen; Hong Kan; Gerry Hobbs; Mitchell S Finkel
Journal:  J Appl Physiol (1985)       Date:  2009-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.